Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Teva’s New Treatment for Huntington’s Disease Approved by FDA


According to a press release issued by the company, it’s been nearly ten years since a new drug for chorea associated with Huntington’s disease has been approved by the regulator.

Share this!

April 6, 2017 | by Sarah Hand, M.Sc.

Teva Pharmaceuticals’ Huntington’s Disease drug, Austedo (deutetrabenazine), has been approved by the FDA for the treatment of involuntary movements associated with the disorder, known as chorea. According to a press release issued by the company, it’s been nearly ten years since a new drug for chorea associated with Huntington’s disease has been approved by the regulator.

“Chorea is a major symptom for many living with Huntington disease. It impacts patients’ functionality and activities of daily living, and there have been limited treatment options for these patients,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva. “Based on the results demonstrated in the clinical development program which supported the approval of Austedo and our ongoing commitment to patients, we feel uniquely positioned to bring this treatment option forward.”

Huntington’s disease is a rare and often fatal neurodegenerative disorder which affects over 35,000 patients in the US. Around 90 percent of these patients experience symptoms of chorea, including sudden and involuntary twisting and writhing movements.

The results from two Phase III clinical trials – FIRST-HD and ARC-HD – were used to support the FDA’s decision to approve Austedo. The FIRST-HD study provided evidence that Austedo was able to reduce chorea in patients, compared to a placebo. Patients who were taking tetrabenazine, the only other FDA approved treatment for chorea, were able to switch to Austedo without losing symptom control, in the ARC-HD clinical trial.

“Chorea associated with Huntington’s disease has a significant impact on those living with the disease and their families,” said Louise Vetter, CEO of the Huntington’s Disease Society of America. “The FDA’s approval of Austedo represents an important new treatment option for people with HD and highlights the need for more therapeutic resources for this underserved patient community.”

Austedo is a small molecule drug designed to regulate neuronal levels of dopamine. The drug does carry a warning that Austedo can increase the risk of depression and suicidal ideation in patients with Huntington’s disease, which could limit its use.

Teva added Austedo to their portfolio after the 2015 acquisition of Auspex Pharmaceuticals. The FDA granted Orphan Drug Designation to Austedo in late 2014.

Keywords:  FDA, Huntington's Disease, Dopamine


Share this with your colleagues!

Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News

FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News

Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


Technology Solutions for Late Phase Research: Optimising Real World Data Assets

Serialization for Late Starters – With Live Industry Research Results

Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse

The New Gold Standards of IRT Delivery for Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.